US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

BiondVax Pharmaceuticals Ltd. - American Depositary Shares (NQ:BVXV)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BiondVax Pharmaceuticals Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Equity Research Report
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports FY 2022 Financial Statements, Corporate Update
Via Investor Brand Network
Biden Signs Measure to End National COVID-19 Emergency
Via Investor Brand Network
Topics Government
Eczema or Asthma Predisposes Individuals to Osteoarthritis
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland
Via Investor Brand Network
News headline image
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities
Via Investor Brand Network
New Approach Could Boost Current Asthma Medication Efficacy
Via Investor Brand Network
Risk Factors of Age-Related Macular Degeneration
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
Via Investor Brand Network
Scientists Sound Alarm on Climate-Change-Induced Rise of Deadly infections
Via Investor Brand Network
Topics Climate Change
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants
Via Investor Brand Network
Japan to Categorize COVID-19 as Common Infectious Illness
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring
Via Investor Brand Network
News headline image
BiondVax to Present at BIO-Europe Spring
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Study Shows Air Pollution in Urban Areas Worsens Lung Function in Kids
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders
Via Investor Brand Network
News headline image
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Climate Change Heightening Risk of Global Infectious Illnesses
Via Investor Brand Network
Topics Climate Change
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), Collaborators Positioned to Rapidly Develop Neutralizing NanoAbs for Emerging COVID-19 Variants
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Nano-sized Molecules Show Powerful Impact in Preclinical Studies
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) NanoAb Product Shows Preclinical Promise as COVID Preventative for consumers Hit by Evusheld’s EUA Withdrawal
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages
Via Investor Brand Network
Study Finds Common Fatty Acid May Increase Pain, Temperature Sensitivity in Psoriasis
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 Next >